Standard Lithium Prices Upsized $130 Million Underwritten Public Offering

VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE.A: SLI), a leading near-commercial lithium company, announced the pricing of its previously announced underwritten public offering (the “Offering”) of 29,885,057 common shares (the “Common Shares”) at a price of US $4.35 per Common Share (the “Issue Price”) for aggregate gross proceeds to the Company of US $130 million.

The Offering is being conducted through a syndicate of underwriters led by Morgan Stanley and Evercore ISI as co-lead book-running managers and includes BMO Capital Markets, as a book-running manager, Canaccord Genuity, Raymond James, Roth Capital Partners and Stifel (together, the “Underwriters”).

The Company has granted the Underwriters an option to purchase up to 4,482,758 additional Common Shares (the “Over-Allotment Option”) at the Issue Price, exercisable, in whole or in part, for up to 30 days after the closing of the Offering.

The Company intends to use the net proceeds from the Offering to fund capital expenditures at the South West Arkansas Project and the Franklin Project in East Texas (each, as defined in the Prospectus Supplement (defined below)), and for working capital and for general corporate purposes.

Closing of the Offering is expected to occur on or about October 20, 2025, and is subject to customary closing conditions, including receipt of required approvals of the TSX Venture Exchange (“TSXV”) and the NYSE American.

In connection with the Offering, the Company filed, with the securities commissions in all of the provinces and territories of Canada other than Quebec, a preliminary prospectus supplement (the “Prospectus Supplement”) to the Company’s existing base shelf prospectus (the “Base Shelf Prospectus”) filed with the securities commissions in each of the provinces and territories of Canada, and filed a preliminary prospectus supplement in the United States (the “U.S. Prospectus Supplement”, together with the Prospectus Supplement, the “Prospectus Supplements”) to the Company’s existing base shelf prospectus (the “U.S. Base Shelf Prospectus”, together with the Base Shelf Prospectus, the “Base Shelf Prospectuses”) forming part of an effective registration statement on Form F-10 (File No. 333-289110) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (“SEC”) under the U.S./Canada Multijurisdictional Disclosure System.